Summary
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
A1M Pharma AB
Adrenomed AG
Am-Pharma B.V.
Angion Biomedica Corp.
Atox Bio Ltd.
Cellmid Limited
Complexa, Inc.
DiaMedica Inc.
Digna Biotech, S.L.
DURECT Corporation
F. Hoffmann-La Roche Ltd.
G1 Therapeutics, Inc.
Kringle Pharma, Inc.
NephroGene
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 23
A1M Pharma AB 23
Adrenomed AG 24
Am-Pharma B.V. 25
Angion Biomedica Corp. 26
Atox Bio Ltd. 27
Cellmid Limited 28
Complexa, Inc. 29
DiaMedica Inc. 30
Digna Biotech, S.L. 31
DURECT Corporation 32
F. Hoffmann-La Roche Ltd. 33
G1 Therapeutics, Inc. 34
Kringle Pharma, Inc. 35
NephroGenex, Inc. 36
NeuroVive Pharmaceutical AB 37
Noorik Biopharmaceuticals AG 38
Noxxon Pharma AG 39
Orion Oyj 40
ProMetic Life Sciences Inc. 41
Quark Pharmaceuticals, Inc. 42
SBI Pharmaceuticals Co., Ltd. 43
Spherium Biomed S.L. 44
STATegics, Inc. 45
Stealth BioTherapeutics Inc. 46
Thrasos Therapeutics Inc. 47
Torrent Pharmaceuticals Limited 48
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Target 51
Assessment by Mechanism of Action 53
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
A1M-001 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
AB-103 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
adrecizumab - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
BB-3 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
CAB-101 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Cardiotrophin-1 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
CXA-10 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
cyclosporine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
DM-199 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
DUR-928 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
elamipretide - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
HYPER-IL-6 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
KP-100IT - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
levosimendan - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
MG-53 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
MIX-9 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
N-003 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
NOXD-21 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
PBI-4419 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Pyridoxamine Dihydrochloride - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
QPI-1002 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
R-190 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
RLS-003 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
RO-6839328 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
SP-15016 - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
STSE-15 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
THR-184 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
TRC-160334 - Drug Profile 127
Product Description 127
Mechanism Of Action 127
R&D Progress 127
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 128
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 129
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 130
Featured News & Press Releases 130
Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment 130
May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial 131
Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury 131
Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation 132
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 132
Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI) 133
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 133
Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury 134
Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study 135
Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision 135
Nov 04, 2015: DiaMedica Provides Corporate Update 136
Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin 137
Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego 137
Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials 138
Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury 138
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2016 23
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2016 24
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2016 25
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2016 26
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd., H2 2016 27
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2016 28
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2016 29
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2016 30
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2016 31
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2016 32
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2016 34
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2016 35
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2016 36
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 37
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2016 38
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noxxon Pharma AG, H2 2016 39
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2016 40
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2016 41
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 42
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 43
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed S.L., H2 2016 44
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2016 45
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc., H2 2016 46
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc., H2 2016 47
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 48
Assessment by Monotherapy Products, H2 2016 49
Assessment by Combination Products, H2 2016 50
Number of Products by Stage and Target, H2 2016 52
Number of Products by Stage and Mechanism of Action, H2 2016 54
Number of Products by Stage and Route of Administration, H2 2016 56
Number of Products by Stage and Molecule Type, H2 2016 58
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2016 128
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2016 129
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 49
Number of Products by Top 10 Targets, H2 2016 51
Number of Products by Stage and Top 10 Targets, H2 2016 51
Number of Products by Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Routes of Administration, H2 2016 55
Number of Products by Stage and Routes of Administration, H2 2016 55
Number of Products by Molecule Types, H2 2016 57
Number of Products by Stage and Molecule Types, H2 2016 57
